Plasma-Derived Therapeutics Market to Reach US$ 35.10 Billion by 2033 at 6.4% CAGR; North America Leads with 45% Share - Key Players: Takeda, Grifols, CSL

The Global Plasma-Derived Therapeutics Market was valued at US$ 20.16 billion in 2023, increased to US$ 21.26 billion in 2024, and is expected to reach US$ 35.10 billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033. The market is expanding steadily as the demand for plasma-derived therapies rises to address rare, chronic, and life-threatening conditions worldwide.

Plasma-derived therapeutics include products such as immunoglobulins, clotting factors, and albumin, used to treat conditions like primary immunodeficiency, hemophilia, autoimmune disorders, and chronic liver disease. Market growth is driven by the increasing prevalence of these disorders, higher diagnosis rates, and growing awareness of the clinical benefits of plasma-based treatments. Technological advancements in plasma collection, fractionation, and purification have enhanced therapy safety, efficacy, and accessibility, while supportive regulatory frameworks and streamlined approval processes have accelerated adoption. Furthermore, ongoing R&D and collaborations within the biopharmaceutical industry are expanding the therapeutic potential of plasma-derived products, with next-generation immunoglobulins and recombinant plasma alternatives poised to further transform patient care.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/plasma-derived-therapeutics-market?sai-v

The Plasma-Derived Therapeutics Market is the sector that develops and supplies therapeutic products derived from human plasma to treat immune deficiencies, bleeding disorders, and other medical conditions.

Key Developments
✅ December 2025: Regulatory approvals and expanded access programs increased adoption of plasma-derived therapies for immune deficiencies, hemophilia, and rare blood disorders.

✅ October 2025: Advances in fractionation technologies and viral inactivation methods improved safety, purity, and yield of plasma-derived therapeutics.

✅ August 2025: Integration of recombinant and plasma-derived products enhanced combination therapy approaches for rare and chronic diseases.

✅ June 2025: Pharmaceutical companies expanded investment in plasma collection centers and supply chain infrastructure to meet growing global demand.

✅ March 2025: Clinical trials and R&D focused on novel indications and formulations of immunoglobulins, clotting factors, and albumin-based therapies, strengthening the pipeline of plasma-derived products.

Mergers & Acquisitions
✅ December 2025: A major biopharmaceutical company acquired a plasma-derived therapeutics firm to enhance its portfolio in immunology, hematology, and rare disease treatments.

✅ October 2025: Strategic collaborations were formed between plasma collection organizations and pharmaceutical companies to optimize supply and expand global distribution.

✅ August 2025: Plasma fractionation technology providers partnered with biotech companies to co-develop next-generation plasma-derived therapies.

✅ June 2025: Contract manufacturing and R&D firms entered alliances with plasma therapeutics developers to scale production and improve regulatory compliance.

✅ March 2025: Academic institutions and early-stage biotech startups collaborated with industry players to accelerate innovation in plasma-based biologics and therapeutic applications.

Key Players
Takeda Pharmaceutical Company Limited | Johnson & Johnson (DePuy Synthes) | Octapharma AG | Arthrex, Inc. | Grifols, S.A. | ADMA Biologics, Inc. | CSL | Evolve Biologics Inc. | Kamada Pharmaceuticals | Bio Products Laboratory Ltd

Key Highlights

Takeda Pharmaceutical Company Limited - Holds a share of 15.3%: Leads in plasma-derived therapies with a focus on immunoglobulins, clotting factors, and specialty plasma products for rare and chronic conditions.

Johnson & Johnson (DePuy Synthes) - Holds a share of 12.7%: Develops plasma-based biologics and recombinant products supporting regenerative medicine, immunotherapy, and orthopedic applications.

Octapharma AG - Holds a share of 13.4%: Specializes in human protein therapies derived from plasma, including coagulation factors and immunoglobulins for critical care and chronic diseases.

Arthrex, Inc. - Holds a share of 6.2%: Focuses on biologic and plasma-based orthopedic therapies, enhancing tissue repair, regenerative procedures, and surgical outcomes.

Grifols, S.A. - Holds a share of 16.1%: Global leader in plasma collection and manufacturing of immunoglobulins, albumin, and coagulation factor therapies for a wide range of indications.

ADMA Biologics, Inc. - Holds a share of 5.4%: Develops specialty plasma-derived immunoglobulin therapies targeting immune deficiencies and infectious diseases.

CSL - Holds a share of 14.8%: Offers a broad portfolio of plasma-derived therapeutics including immunoglobulins, albumin, and coagulation products, with a strong global presence.

Evolve Biologics Inc. - Holds a share of 3.9%: Focuses on niche plasma-based therapies and biologics targeting rare and underserved medical conditions.

Kamada Pharmaceuticals - Holds a share of 4.6%: Develops immunoglobulin and specialty plasma therapies, emphasizing quality and regulatory compliance for global markets.

Bio Products Laboratory Ltd - Holds a share of 6.6%: Manufactures plasma-derived therapeutics, including immunoglobulins and clotting factors, supporting both domestic and international healthcare needs.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=plasma-derived-therapeutics-market?sai-v
(Purchase 2 or more Reports and get 50% discount)

Market Drivers
- Rising prevalence of immune deficiencies, hemophilia, and other chronic blood disorders.

- Growing demand for plasma-derived therapies such as immunoglobulins, clotting factors, and albumin.

- Increasing awareness about rare diseases and the benefits of plasma-derived treatments.

- Advancements in plasma fractionation, purification technologies, and recombinant plasma products.

- Expansion of plasma collection centers and improved donor recruitment strategies.

- Supportive regulatory frameworks for plasma collection and therapeutic product approval.

- Rising adoption of plasma-derived therapies in emerging markets due to improving healthcare infrastructure.

Industry Developments
- Launch of novel immunoglobulin therapies and specialized plasma products for rare diseases.

- Expansion of plasma collection and fractionation facilities to meet growing demand.

- Growing partnerships between plasma therapy manufacturers, hospitals, and healthcare providers.

- Advancements in recombinant plasma proteins and innovative formulation technologies.

- Integration of digital platforms for donor management and plasma supply chain optimization.

- Rising mergers, acquisitions, and strategic investments in plasma-derived therapeutics companies.

- Expansion of clinical trials to evaluate efficacy and safety of new plasma-derived treatments.

Regional Insights
North America - 45% share: Driven by strong plasma collection infrastructure, high prevalence of chronic blood disorders, and established pharmaceutical manufacturing.

Europe - 28% share: Supported by robust regulatory frameworks, growing plasma donation networks, and increasing adoption of plasma-derived therapies.

Asia Pacific - 20% share: Fueled by expanding healthcare infrastructure, rising awareness, and increasing plasma collection initiatives.

Latin America - 4% share: Boosted by improving healthcare facilities, increasing plasma donation awareness, and gradual adoption of plasma therapies.

Middle East & Africa - 3% share: Driven by investments in healthcare modernization, increasing plasma donation, and rising availability of plasma-derived products.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/plasma-derived-therapeutics-market?sai-v

Key Segments
➥ By Product Type
Protein: Therapeutic proteins used to replace or supplement deficient or dysfunctional proteins in patients, supporting normal physiological functions.

Coagulation Factors: Purified or recombinant clotting factors (e.g., Factor VIII, Factor IX) used to treat bleeding disorders such as hemophilia.

Others: Includes immune globulins, enzyme replacement therapies, and other biologics used in blood-related disorders and immunodeficiencies.

➥ By Application
Hemophilia: Treatment of congenital bleeding disorders through replacement therapy with coagulation factors or protein-based therapeutics.

Idiopathic Thrombocytopenic Purpura (ITP): Therapeutics aimed at managing low platelet counts, reducing bleeding risk, and improving patient outcomes.

Primary Immunodeficiencies: Use of protein-based therapies or immunoglobulins to restore immune function in patients with inherited immune system deficiencies.

Others: Covers treatment of rare bleeding disorders, acquired immunodeficiencies, and supportive therapies for hematologic conditions.

➥ By End-User
Hospitals & Specialty Clinics: Facilities providing inpatient and outpatient management of bleeding and immunodeficiency disorders, including administration of protein and coagulation therapies.

Ambulatory Surgical Centers: Outpatient centers performing procedures requiring perioperative management of bleeding disorders and specialized therapies.

Homecare Services: Delivery and administration of biologic therapies, such as coagulation factors and protein treatments, in home settings for chronic management.

Others: Includes research institutions, specialty pharmacies, and long-term care facilities supporting treatment and distribution of hematologic therapies.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.